# S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

> **NCT00003416** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 9 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** dexamethasone
- **DRUG:** melphalan
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00003416
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 2000-08
- **Final completion:** 2004-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2015-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003416, "S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00003416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*